Treatment of Friedreich Ataxia in Adults with Diabetes Mellitus

Clinical Scenario

This protocol addresses adults (18 years or older) diagnosed with Friedreich ataxia who also have diabetes mellitus. Concurrent diabetes is a recognised comorbidity in this population and requires deliberate clinical management alongside the underlying neurological condition.

Diabetes Mellitus in Friedreich Ataxia

There is insufficient evidence to favor a single standardised first-line approach for adults with lower-risk diabetes mellitus and Friedreich ataxia. Treatment decisions must account for individual patient factors — heterogeneity in how this comorbidity presents in Friedreich ataxia makes a one-size-fits-all approach inappropriate.

Treatment Approach — Partial Overview

Management centres on an individualized selection of glucose-lowering therapy, with the choice guided by the patient's clinical profile and risk level. The complete algorithm — including how different risk presentations determine the therapeutic path — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s13023-022-02568-3

There is insufficient evidence to favor either insulin alone or metformin or novel glucose-lowering therapies (e.g., SGLT2i, GLP1RA, DPPIVi) as initial therapy for adults with lower-risk diabetes mellitus (HbA1c < 8.5%, no ketones, no acute hyperglycemia) with Friedreich ataxia.
We suggest an individualized approach with either insulin alone, and/or a glucose-lowering agent, with the choice of medication patient dependent, particularly because of the heterogeneity in Friedreich ataxia-related diabetes mellitus.
Insulin is an appropriate treatment but possible risks and benefits of adding other medications are unknown in Friedreich ataxia and treatments must be individualized.

View source ↗